Need help finding what you are looking for?
Contact Us
PUBLISHER: Transparency Market Research | PRODUCT CODE: 1140622
PUBLISHER: Transparency Market Research | PRODUCT CODE: 1140622
Benign Prostatic Hyperplasia Treatment Market (Treatment: Drug Class, Minimally Invasive Surgeries, Laser Therapy, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
PUBLISHED:
PAGES: 214 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
The report provides revenue of the global benign prostatic hyperplasia treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global benign prostatic hyperplasia treatment market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the benign prostatic hyperplasia treatment market.
The report delves into the competitive landscape of the global benign prostatic hyperplasia treatment market. Key players operating in the global benign prostatic hyperplasia treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global benign prostatic hyperplasia treatment market profiled in this report.
Product Code: TMRGL72273
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Benign Prostatic Hyperplasia Treatment Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Segment Definition
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast, 2017-2031
- 4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
- 5.1. Pipeline Analysis
- 5.2. Prevalence of Benign Prostatic Hyperplasia by region/globally
- 5.3. Re-imbursement Scenario
- 5.4. Key Industry Events (mergers, acquisitions, partnerships, etc.)
- 5.5. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast, By Treatment
- 6.1. Introduction & Definition
- 6.2. Key Findings / Developments
- 6.3. Market Value Forecast, by Treatment, 2017-2031
- 6.3.1. Drug Class
- 6.3.1.1. Alpha-Blockers
- 6.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
- 6.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
- 6.3.1.4. Others
- 6.3.2. Minimally Invasive Surgeries
- 6.3.2.1. Transurethral Resection of the Prostate (TURP)
- 6.3.2.2. Transurethral Incision of the Prostate (TUIP)
- 6.3.2.3. Robotic Surgeries
- 6.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
- 6.3.2.5. Prostatic Urethral Lift
- 6.3.3. Laser Therapy
- 6.3.4. Others
- 6.3.1. Drug Class
- 6.4. Market Attractiveness Analysis, by Treatment
7. Global Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast, by End-user
- 7.1. Introduction & Definition
- 7.2. Key Findings / Developments
- 7.3. Market Value Forecast, by End-user, 2017-2031
- 7.3.1. Hospitals
- 7.3.2. Ambulatory Surgical Centers
- 7.3.3. Specialty Clinics
- 7.3.4. Others
- 7.4. Market Attractiveness Analysis, by End-user
8. Global Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast, by Region
- 8.1. Key Findings
- 8.2. Market Value Forecast, by Region
- 8.2.1. North America
- 8.2.2. Europe
- 8.2.3. Asia Pacific
- 8.2.4. Latin America
- 8.2.5. Middle East & Africa
- 8.3. Market Attractiveness Analysis, by Region
9. North America Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast
- 9.1. Introduction
- 9.1.1. Key Findings
- 9.2. Market Value Forecast, by Treatment, 2017-2031
- 9.2.1. Drug Class
- 9.2.1.1. Alpha-Blockers
- 9.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
- 9.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
- 9.2.1.4. Others
- 9.2.2. Minimally Invasive Surgeries
- 9.2.2.1. Transurethral Resection of the Prostate (TURP)
- 9.2.2.2. Transurethral Incision of the Prostate (TUIP)
- 9.2.2.3. Robotic Surgeries
- 9.2.2.4. Transurethral Microwave Thermotherapy (TUMT
- 9.2.2.5. Prostatic Urethral Lift
- 9.2.3. Laser Therapy
- 9.2.4. Others
- 9.2.1. Drug Class
- 9.3. Market Value Forecast, by End-user, 2017-2031
- 9.3.1. Hospitals
- 9.3.2. Ambulatory Surgical Centers
- 9.3.3. Specialty Clinics
- 9.3.4. Others
- 9.4. Market Value Forecast, by Country, 2017-2031
- 9.4.1. U.S.
- 9.4.2. Canada
- 9.5. Market Attractiveness Analysis
- 9.5.1. By Treatment
- 9.5.2. By End-user
- 9.5.3. By Country
10. Europe Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast
- 10.1. Introduction
- 10.1.1. Key Findings
- 10.2. Market Value Forecast, by Treatment, 2017-2031
- 10.2.1. Drug Class
- 10.2.1.1. Alpha-Blockers
- 10.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
- 10.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
- 10.2.1.4. Others
- 10.2.2. Minimally Invasive Surgeries
- 10.2.2.1. Transurethral Resection of the Prostate (TURP)
- 10.2.2.2. Transurethral Incision of the Prostate (TUIP)
- 10.2.2.3. Robotic Surgeries
- 10.2.2.4. Transurethral Microwave Thermotherapy (TUMT)
- 10.2.2.5. Prostatic Urethral Lift
- 10.2.3. Laser Therapy
- 10.2.4. Others
- 10.2.1. Drug Class
- 10.3. Market Value Forecast, by End-user, 2017-2031
- 10.3.1. Hospitals
- 10.3.2. Ambulatory Surgical Centers
- 10.3.3. Specialty Clinics
- 10.3.4. Others
- 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 10.4.1. Germany
- 10.4.2. U.K.
- 10.4.3. France
- 10.4.4. Spain
- 10.4.5. Italy
- 10.4.6. Rest of Europe
- 10.5. Market Attractiveness Analysis
- 10.5.1. By Treatment
- 10.5.2. By End-user
- 10.5.3. By Country/Sub-region
11. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast
- 11.1. Introduction
- 11.1.1. Key Findings
- 11.2. Market Value Forecast, by Treatment, 2017-2031
- 11.2.1. Drug Class
- 11.2.1.1. Alpha-Blockers
- 11.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
- 11.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
- 11.2.1.4. Others
- 11.2.2. Minimally Invasive Surgeries
- 11.2.2.1. Transurethral Resection of the Prostate (TURP)
- 11.2.2.2. Transurethral Incision of the Prostate (TUIP)
- 11.2.2.3. Robotic Surgeries
- 11.2.2.4. Transurethral Microwave Thermotherapy (TUMT)
- 11.2.2.5. Prostatic Urethral Lift
- 11.2.3. Laser Therapy
- 11.2.4. Others
- 11.2.1. Drug Class
- 11.3. Market Value Forecast, by End-user, 2017-2031
- 11.3.1. Hospitals
- 11.3.2. Ambulatory Surgical Centers
- 11.3.3. Specialty Clinics
- 11.3.4. Others
- 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.4.1. China
- 11.4.2. Japan
- 11.4.3. India
- 11.4.4. Australia & New Zealand
- 11.4.5. Rest of Asia Pacific
- 11.5. Market Attractiveness Analysis
- 11.5.1. By Treatment
- 11.5.2. By End-user
- 11.5.3. By Country/Sub-region
12. Latin America Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast
- 12.1. Introduction
- 12.1.1. Key Findings
- 12.2. Market Value Forecast, by Treatment, 2017-2031
- 12.2.1. Drug Class
- 12.2.1.1. Alpha-Blockers
- 12.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
- 12.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
- 12.2.1.4. Others
- 12.2.2. Minimally Invasive Surgeries
- 12.2.2.1. Transurethral Resection of the Prostate (TURP)
- 12.2.2.2. Transurethral Incision of the Prostate (TUIP)
- 12.2.2.3. Robotic Surgeries
- 12.2.2.4. Transurethral Microwave Thermotherapy (TUMT)
- 12.2.2.5. Prostatic Urethral Lift
- 12.2.3. Laser Therapy
- 12.2.4. Others
- 12.2.1. Drug Class
- 12.3. Market Value Forecast, by End-user, 2017-2031
- 12.3.1. Hospitals
- 12.3.2. Ambulatory Surgical Centers
- 12.3.3. Specialty Clinics
- 12.3.4. Others
- 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.4.1. Brazil
- 12.4.2. Mexico
- 12.4.3. Rest of Latin America
- 12.5. Market Attractiveness Analysis
- 12.5.1. By Treatment
- 12.5.2. By End-user
- 12.5.3. By Country/Sub-region
13. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast
- 13.1. Introduction
- 13.1.1. Key Findings
- 13.2. Market Value Forecast, by Treatment, 2017-2031
- 13.2.1. Drug Class
- 13.2.1.1. Alpha-Blockers
- 13.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
- 13.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
- 13.2.1.4. Others
- 13.2.2. Minimally Invasive Surgeries
- 13.2.2.1. Transurethral Resection of the Prostate (TURP)
- 13.2.2.2. Transurethral Incision of the Prostate (TUIP)
- 13.2.2.3. Robotic Surgeries
- 13.2.2.4. Transurethral Microwave Thermotherapy (TUMT)
- 13.2.2.5. Prostatic Urethral Lift
- 13.2.3. Laser Therapy
- 13.2.4. Others
- 13.2.1. Drug Class
- 13.3. Market Value Forecast, by End-user, 2017-2031
- 13.3.1. Hospitals
- 13.3.2. Ambulatory Surgical Centers
- 13.3.3. Specialty Clinics
- 13.3.4. Others
- 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.4.1. GCC Countries
- 13.4.2. South Africa
- 13.4.3. Rest of Middle East & Africa
- 13.5. Market Attractiveness Analysis
- 13.5.1. By Treatment
- 13.5.2. By End-user
- 13.5.3. By Country/Sub-region
14. Competition Landscape
- 14.1. Market Player - Competition Matrix (by tier and size of companies)
- 14.2. Market Share Analysis, by Company, 2021
- 14.3. Company Profiles
- 14.3.1. Boston Scientific Corporation
- 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.1.2. Product Portfolio
- 14.3.1.3. Financial Overview
- 14.3.1.4. SWOT Analysis
- 14.3.1.5. Strategic Overview
- 14.3.2. Teleflex Incorporated
- 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.2.2. Product Portfolio
- 14.3.2.3. Financial Overview
- 14.3.2.4. SWOT Analysis
- 14.3.2.5. Strategic Overview
- 14.3.3. Endo International plc
- 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.3.2. Product Portfolio
- 14.3.3.3. Financial Overview
- 14.3.3.4. SWOT Analysis
- 14.3.3.5. Strategic Overview
- 14.3.4. Urologix, LLC
- 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.4.2. Product Portfolio
- 14.3.4.3. Financial Overview
- 14.3.4.4. SWOT Analysis
- 14.3.3.5. Strategic Overview
- 14.3.5. LISA Laser
- 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.5.2. Product Portfolio
- 14.3.5.3. Financial Overview
- 14.3.5.4. SWOT Analysis
- 14.3.5.5. Strategic Overview
- 14.3.6. Olympus Corporation
- 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.6.2. Product Portfolio
- 14.3.6.3. Financial Overview
- 14.3.6.4. SWOT Analysis
- 14.3.6.5. Strategic Overview
- 14.3.1. Boston Scientific Corporation
Product Code: TMRGL72273
List of Tables
- Table 01: Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Treatment 2017-2031
- Table 02: Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Drug Class 2017-2031
- Table 03: Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Minimally Invasive Surgeries2017-2031
- Table 04: Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2031
- Table 05: Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
- Table 06: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
- Table 07: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Treatment 2017-2031
- Table 08: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Drug Class 2017-2031
- Table 09: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Minimally Invasive Surgeries2017-2031
- Table 10: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2031
- Table 11: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
- Table 12: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017-2031
- Table 13: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Treatment 2017-2031
- Table 14: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Drug Class 2017-2031
- Table 15: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Minimally Invasive Surgeries2017-2031
- Table 16: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2031
- Table 17: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
- Table 18: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017-2031
- Table 19: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Treatment 2017-2031
- Table 20: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Drug Class 2017-2031
- Table 21: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017-2031
- Table 22: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2031
- Table 23: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
- Table 24: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017-2031
- Table 25: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Treatment 2017-2031
- Table 26: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Drug Class 2017-2031
- Table 27: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Minimally Invasive Surgeries2017-2031
- Table 28: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2031
- Table 29: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
- Table 30: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017-2031
- Table 31: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Treatment 2017-2031
- Table 32: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Drug Class 2017-2031
- Table 33: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Minimally Invasive Surgeries2017-2031
- Table 34: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2031
- Table 35: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
List of Figures
- Figure 01: Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, 2017-2031
- Figure 02: Global Benign Prostatic Hyperplasia Treatment Market Value Share, by Treatment, 2021
- Figure 03: Global Benign Prostatic Hyperplasia Treatment Market Value Share, by End-user, 2021
- Figure 04: Global Benign Prostatic Hyperplasia Treatment Market, by Treatment, 2021 and 2031
- Figure 05: Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment, 2021-2031
- Figure 06: Global Benign Prostatic Hyperplasia Treatment Market, by Drug Class, 2021-2031
- Figure 07: Global Benign Prostatic Hyperplasia Treatment Market, by Minimally Invasive Surgeries, 2021-2031
- Figure 08: Global Benign Prostatic Hyperplasia Treatment Market, by Laser Therapy, 2021-2031
- Figure 09: Global Benign Prostatic Hyperplasia Treatment Market, by Others, 2021-2031
- Figure 10: Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Drug Class, 2021-2031
- Figure 11: Global Benign Prostatic Hyperplasia Treatment Market, by End-user, 2021 and 2031
- Figure 12: Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user, 2021-2031
- Figure 13: Global Benign Prostatic Hyperplasia Treatment Market (US$ Mn), by Hospitals, 2017-2031
- Figure 14: Global Benign Prostatic Hyperplasia Treatment Market (US$ Mn), by Ambulatory Surgical Centers, 2017-2031
- Figure 15: Global Benign Prostatic Hyperplasia Treatment Market (US$ Mn), by Specialty Clinics, 2017-2031
- Figure 16: Global Benign Prostatic Hyperplasia Treatment Market (US$ Mn), by Others, 2017-2031
- Figure 17: Global Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Region, 2021 and 2031
- Figure 18: Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Region, 2017-2031
- Figure 19: North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, 2017-2031
- Figure 20: North America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Country, 2021 and 2031
- Figure 21: North America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
- Figure 22: North America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031
- Figure 23: North America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment, 2021-2031
- Figure 24: North America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2021 and 2031
- Figure 25: North America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user, 2021-2031
- Figure 26: Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, 2017-2031
- Figure 27: Europe Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
- Figure 28: Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
- Figure 29: Europe Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031
- Figure 30: Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment, 2021-2031
- Figure 31: Europe Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2021 and 2031
- Figure 32: Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user, 2021-2031
- Figure 33: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, 2017-2031
- Figure 34: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
- Figure 35: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
- Figure 36: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031
- Figure 37: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment, 2021-2031
- Figure 38: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2021 and 2031
- Figure 39: Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user, 2021-2031
- Figure 40: Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, 2017-2031
- Figure 41: Latin America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
- Figure 42: Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
- Figure 43: Latin America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031
- Figure 44: Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment, 2021-2031
- Figure 45: Latin America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2021 and 2031
- Figure 46: Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user, 2021-2031
- Figure 47: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, 2017-2031
- Figure 48: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
- Figure 49: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
- Figure 50: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2021 and 2031
- Figure 51: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment, 2021-2031
- Figure 52: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2021 and 2031
- Figure 53: Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user, 2021-2031
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.